Physician profile
Scott B Parry
NPI 1306860101
$162,198.32
in general payments reported to CMS, 2019-2025
68 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,799 · 2020: $1,934 · 2021: $16K · 2022: $26K · 2023: $62K · 2024: $37K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $98K · Food and Beverage: $12K · Travel and Lodging: $5,551 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $98,360.00 |
| Food and Beverage | $11,828.38 |
| Travel and Lodging | $5,550.57 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $120,482.71 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $26,789.19 | 2019-2025 | Descovy, Yeztugo, Biktarvy |
| Abbvie INC. | $1,533.64 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,492.23 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Novo Nordisk INC | $1,102.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Biotech, INC. | $972.32 | 2019-2023 | Symtuza |
| Antares Pharma, INC. | $733.98 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Pfizer INC. | $623.30 | 2019-2025 | |
| Emd Serono, INC. | $551.93 | 2019-2025 | Serostim |
| Allergan, INC. | $550.58 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $442.30 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Theratechnologies INC. | $440.85 | 2019-2025 | Egrifta, Trogarzo |
| Lilly USA, LLC | $355.40 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $348.09 | 2019-2024 | Trintellix |
| Amgen INC. | $342.26 | 2019-2025 | Repatha, Otezla, Repatha |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Parry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.